Jian‐Hong Zhong

机构：Guangxi Medical University, Guangxi Center for Disease Prevention and Control, Tumor Hospital of Guangxi Medical University · ORCID：0000-0002-1494-6396

发表论文 335 篇 · 总被引 6944 次 · h-index 42

代表论文

• Tertiary lymphoid structures in HCC: Influence on immune cell profiles in tumors and on efficacy of adjuvant PD-1 inhibitor therapy after hepatectomy (2025 · Hepatology · 被引 14)
• First-line tislelizumab and ociperlimab combined with gemcitabine and cisplatin in advanced biliary tract cancer (ZSAB-TOP): a multicenter, single-arm, phase 2 study (2025 · Signal Transduction and Targeted Therapy · 被引 8)
• Prognostic value of radiological and pathological complete response following immune-based conversion therapy in patients with unresectable hepatocellular carcinoma (GUIDANCE004) (2025 · JHEP Reports · 被引 7)
• Adjuvant Transarterial Chemoembolization After Truly Curative Resection Does Not Improve Survival of Patients With Hepatocellular Carcinoma at High Risk of Recurrence: A Target Trial Emulation Study (2025 · Hepatology Research · 被引 7)
• Erratum: Multicenter, retrospective GUIDANCE001 study comparing transarterial chemoembolization with or without tyrosine kinase and immune checkpoint inhibitors as conversion therapy to treat unresectable hepatocellular carcinoma: Survival benefit in intermediate or advanced, but not early, stages (2025 · Hepatology · 被引 4)
• The efficacy and safety of tislelizumab with or without tyrosine kinase inhibitor as adjuvant therapy in hepatocellular carcinoma with high-risk of recurrence after curative resection (2025 · Frontiers in Immunology · 被引 4)